Summary
MDAI was developed as a putatively non-neurotoxic MDMA analogue, but research indicates it may still cause neurotoxicity when combined with amphetamines or used chronically. Three UK deaths in 2011-2012 were linked to MDAI use with serotonin syndrome as a suspected factor. The substance should be accurately weighed on a milligram scale due to variable purity. Users should be aware that MDAI is primarily sedating rather than stimulating, lacks the dopaminergic effects of MDMA, and is often described as producing empathogenic effects without euphoric stimulation. Set and setting remain important considerations.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 40-100mg | 100-175mg | 175-300mg | 300mg+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects | Total |
|---|---|---|---|---|---|---|
| Oral | 19-40 min | 30-60 min | 2.0-2.5 hrs | 1.0-2.0 hrs | 12.0 hrs | 4.0-6.0 hrs |
Tolerance
Build-up
develops rapidly after a single use
Reset
7–14 days for baseline
Effects
Positive
- Physical Euphoria
- Physical euphoria
- Stimulation
Negative
- Temperature Regulation Suppression
- Nystagmus
- Nausea
- Sedation
- Difficulty Urinating
- Excessive yawning
- Dilated pupils
Positive
- Anxiety Suppression
- Empathy Enhancement
- Sociability Enhancement
- Cognitive Euphoria
- Alertness enhancement
- Emotionality enhancement
- Empathy enhancement
- Cognitive euphoria
- Analysis enhancement
Negative
- Talkativeness
Positive
- Tactile Enhancement
- Music Appreciation
- Tactile enhancement
- Colour enhancement
Negative
- Dehydration
- Light sensitivity
- Spontaneous Physical Sensations
- Perception of bodily heaviness
- Spontaneous physical sensations
- Changes in felt bodily form